# Lymphatic metastasis of papillary thyroid carcinoma: mechanism and clinicopathological physiology

## TL;DR

This review explores how papillary thyroid cancer spreads through the lymphatic system and its impact on diagnosis and treatment.

## Contribution

The paper provides a comprehensive synthesis of the mechanisms and clinical implications of lymphatic metastasis in papillary thyroid carcinoma.

## Key findings

- Lymphatic metastasis occurs in 30–80% of PTC patients and affects clinical management.
- Molecular pathways like VEGF-C/VEGFR-3 and immune evasion drive lymphangiogenesis in PTC.
- High-risk features such as tumor size and molecular markers predict metastatic potential and outcomes.

## Abstract

Lymphatic metastasis is a hallmark feature of papillary thyroid carcinoma (PTC), occurring in 30–80% of patients and significantly influencing clinical management. This review comprehensively examines the biological, anatomical, and clinical characteristics of lymphatic spread in PTC, focusing on its diagnostic and therapeutic implications. We detail the molecular mechanisms driving lymphangiogenesis, including the VEGF-C/VEGFR-3 axis and immune-evasion pathways, and highlight the distinct patterns of regional lymph node involvement—from central compartment (Level VI) to lateral (Levels II–V) and rare skip metastases. High-risk clinicopathological features, such as tumor size >2 cm, extrathyroidal extension, and aggressive histological variants, are discussed alongside molecular markers (BRAF V600E, TERT, RET/PTC) that predict metastatic potential. Management strategies are reviewed, balancing the benefits of prophylactic central neck dissection against its risks and emphasizing risk-adapted radioactive iodine therapy. Despite the frequency of lymphatic metastasis, its prognostic impact varies: microscopic nodal disease has minimal effect on survival, while macroscopic or extranodal extension increases recurrence and mortality risks. This synthesis of current evidence aims to guide clinicians in optimizing detection, treatment, and surveillance for PTC patients with lymphatic metastasis.